Caplin Point Laboratories Ltd
NSE: CAPLIPOINT BSE: 524742
₹1690.10
(0.36%)
Sun, 15 Mar 2026, 03:12 pm
Market Cap128.05B
PE Ratio21.00
Dividend0.36
Health Technology
Pharmaceuticals: Major
24.5KCaplin Point Laboratories Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (13x coverage).
- Dividends after 3 years are expected to be thoroughly covered by earnings (10.6x coverage).
- Dividends per share have been stable in the past 10 years.
- Caplin Point Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Caplin Point Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Cash flow for Caplin Point Laboratories is expected to increase by more than 50% in 2 years time.
- Caplin Point Laboratories's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Caplin Point Laboratories's earnings are expected to exceed the low risk growth rate next year.
- Caplin Point Laboratories is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- Caplin Point Laboratories's revenue growth is expected to exceed the India market average.
- Caplin Point Laboratories's earnings are expected to grow by 18.2% yearly, however this is not considered high growth (20% yearly).
- Caplin Point Laboratories's earnings growth is positive but not above the India market average.
- Caplin Point Laboratories's net income is expected to increase but not above the 50% threshold in 2 years time.
- A decline in Caplin Point Laboratories's performance (ROE) is expected over the next 3 years.
- Caplin Point Laboratories's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Caplin Point Laboratories's revenue is expected to grow by 19.4% yearly, however this is not considered high growth (20% yearly).
health
- Caplin Point Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Caplin Point Laboratories is profitable, therefore cash runway is not a concern.
- Caplin Point Laboratories is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (11634.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 886.7x debt.
- Caplin Point Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (2% vs 0.1% today).
- Caplin Point Laboratories earns more interest than it pays, coverage of interest payments is not a concern.
- Caplin Point Laboratories's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Caplin Point Laboratories board of directors is about average.
- Sridhar's remuneration is lower than average for companies of similar size in India.
- Sridhar's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Caplin Point Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Caplin Point Laboratories is covered by less than 3 analysts.
- Caplin Point Laboratories has significant price volatility in the past 3 months.
past
- Caplin Point Laboratories has delivered over 20% year on year earnings growth in the past 5 years.
- Caplin Point Laboratories used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Caplin Point Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Caplin Point Laboratories's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (33.2% vs 22.7%).
- Caplin Point Laboratories's 1-year earnings growth is less than its 5-year average (33.2% vs 33.8%)
- Caplin Point Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
value
- Caplin Point Laboratories is good value based on expected growth next year.
- Caplin Point Laboratories is good value based on earnings compared to the IN Pharmaceuticals industry average.
- 524742 outperformed the Market in India which returned -14.5% over the past year.
- BSE:524742 is up 19.4% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524742 is up 19.4% outperforming the market in India which returned 8% over the past month.
- Caplin Point Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Caplin Point Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Caplin Point Laboratories is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Caplin Point Laboratories is overvalued based on earnings compared to the India market.
- 524742 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800